SCHEMBL22492925

SCHEMBL22492925

O=C(COc1ccc(CO)cc1)N1CC[C@H](Cc2ccccc2C(F)(F)F)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
POLB P06746 1/20 0.52
ALDH1A1 P00352 6/20 0.47
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 2/20 0.47
RAB9A P51151 1/20 0.47
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
HTT P42858 1/20 0.44
HTR2B P41595 1/20 0.43
MAPK14 Q16539 1/20 0.43
TACR3 P29371 1/20 0.43
PDK2 Q15119 1/20 0.43
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19703260 0.90 MEN1 (0.48) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL22490448 0.86 MEN1 (0.53) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL22493088 0.83 MEN1 (0.55) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL22491610 0.83 MEN1 (0.69) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL19702536 0.81 SCD (0.47) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL19702735 0.81 SCD (0.47) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL19702566 0.81 SCD (0.47) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL19702667 0.80 ALDH1A1 (0.45) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL2819255 0.80 ALDH1A1 (0.49) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL2817672 0.80 ALDH1A1 (0.49) MEN1KMT2APOLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200306248-A1 FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME GDD THERAPEUTICS, LLC (US) 2020-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200306248-A1 FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME SLC7A1, ABCG2, SLC46A1 MEN1 3103/4885KMT2A 4536/4885POLB 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.